In the News
Epigenetic Rejuvenation for Chronic Age-Related Diseases
Every one of the 37 trillion cells in your body has the same DNA code. That base code stays the same from the day you are born until the day you die. So how is it that some cells become the heart, some become bone? And if our DNA doesn’t change as we age, why do we?
Rejuvenate Bio Finds a Home in Sorrento Valley
LIFE SCIENCE: Epigenetics Pioneer Shaping Future of Drug Discovery. “The launch of our new office in this leading biotech hub allows us to aggressively pursue our business development and leverage the talent and expertise San Diego offers,” said Rejuvenate CEO Daniel Oliver
This biotech says mice live longer after genetic reprogramming
The result is a widely anticipated landmark for rejuvenation technology. Noah Davidsohn, chief scientific officer of Rejuvenate, says the company used gene therapy to add three powerful reprogramming genes to the bodies of mice that were equivalent in age to human 77-year-olds.
After the treatment, their remaining life span was doubled, the company says. Treated mice lived another 18 weeks, on average, while control mice died in nine weeks. Overall, the treated mice lived about 7% longer.
Gene therapy may soon help treat mitral valve disease
Two companies are partnering on development of a gene therapy for mitral valve disease in dogs. Phibro Animal Health, an animal nutrition and health products company, and Rejuvenate Bio, which develops gene therapies and other tools to fight age-related diseases of humans and dogs, announced in June they plan to file for conditional approval of their product as early as 2023.
Rejuvenate Bio CEO highlights ambitious approach of using gene therapy to reverse aging
CEO and Co-founder Daniel Oliver shares how he and his co-founder started the company and their vision for treating age-related conditions.
Small Companies, Big Discoveries
“But a new generation of scientists has grabbed hold of the idea with a passion, and an emerging market is taking shape as a result of the effort. Biotech startups are at the forefront of the movement, fusing the highest levels of scientific rigor and ingenuity with the pet owner’s — and their own — experience of the human-animal bond.”
Pet Biotech Roundtable
PetMedix brought together some of the leading companies of the second wave of pet biotech to discuss how we are going to change animal health, why now is the right time for our companies, and what lies ahead for us and the industry as a whole. In this roundtable, PetMedix’s CSO Prof Allan Bradley, Rejuvenate Bio‘s CEO Daniel Oliver, and PetDx‘s CEO Dr Daniel Grosu share their insights and collective experience in human and animal health.
“From a perspective of gene expression, there's nothing to keep your expression profiles the same once you pass the age when you would typically procreate... there's no evolutionary pressure to keep things regulated. We're hoping that with the tools available today, we can piece something together to effectively reverse events that have occurred over your lifetime.”
Nov 30, 2021
Phibro Animal Health Corp. in Teaneck and Rejuvenate Bio Inc. — a spinout from the Wyss Institute at Harvard now based in San Diego — on June 22 announced a collaboration for the development and commercialization of a gene therapy for MVD in dogs.
June 23, 2022
“The myth of a fountain of youth has inspired explorers for centuries, but modern scientists have come closer than any to understanding the secret of long, healthy lives. As it turns out, that secret is genetic.”
“The company raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 diabetes and obesity.”
“It’s a dog’s life – but a new therapy could mean it’s a longer, healthier dog’s life. Rejuvenate Bio has announced it has raised over $10 million in a Series A funding round led by Kendall Capital Partners, a Boston-based firm focused on early-stage biotech companies. Additional investors in-round include gene therapy pioneer Dr Katherine High, V Capital, KdT Ventures and Digitalis Ventures.”
“Harvard Office of Technology Development and the Wyss Institute for Biologically Inspired Engineering at Harvard University announced today that Rejuvenate Bio has been granted an exclusive worldwide license to commercialize a gene therapy technology developed at the Wyss Institute and Harvard Medical School (HMS) to prevent and treat several age-related diseases in dogs, extending their overall healthspan.”
“A single shot of an experimental gene therapy could one day help stall the development of multiple age-related diseases. George Church’s lab at the Wyss Institute of Harvard University has already tested it in mice, and last month a startup called Rejuvenate Bio—founded in 2018 by Church and his former researcher Noah Davidsohn—began a pilot study testing the gene therapy in dogs. If all goes well, they hope that humans will be next.”
“New research from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) suggests that it may be possible someday to tend to multiple ailments with one treatment.”
“The world’s most influential synthetic biologist is behind a new company that plans to rejuvenate dogs using gene therapy. If it works, he plans to try the same approach in people, and he might be one of the first volunteers.
The stealth startup Rejuvenate Bio, cofounded by George Church of Harvard Medical School, thinks dogs aren’t just man’s best friend but also the best way to bring age-defeating treatments to market.”
“Rejuvenate Bio is creating a revolutionary approach to full age reversal. Aging is caused by the dysregulation of multiple systems in the body that manifest itself in age related disease. Current solutions focus on each problem individually, ignoring the interconnectedness of the challenge. Rejuvenate Bio utilizes gene therapy, proprietary targets, and the animal health market to bring anti-aging therapies to market in an incredibly capital-efficient manner.”
“The Wyss Institute for Biologically Inspired Engineering at Harvard Universityannounced today that Rejuvenate Bio has secured an exclusive worldwide license from the Harvard Office of Technology Development to commercialize a gene therapy technology developed at the Wyss Institute and Harvard Medical School (HMS) to prevent and treat several age-related diseases in dogs, extending their overall healthspan. The announcement follows the publication in PNAS of a study led by Harvard researchers detailing the technology's efficacy in mitigating obesity, type II diabetes, heart failure, and renal failure in mice.”
Oct 6, 2021
April 19, 2021
April 26, 2021
Feb 6, 2020
Nov 5, 2019
Nov 4, 2019